Natural Alternatives International Inc. (NAII, Financial) filed Annual Report for the period ended 2010-06-30.
Natural Alternatives International Inc. has a market cap of $55 million; its shares were traded at around $7.75 with a P/E ratio of 11 and P/S ratio of 0.7. NAII is in the portfolios of Jim Simons of Renaissance Technologies LLC.
On December 5, 2005, we acquired Real Health Laboratories, Inc. (RHL), which primarily marketed branded nutritional supplements. On August 4, 2008, we sold certain assets related to RHLs catalog and internet business conducted under the name As We Change® to Miles Kimball Company for a cash purchase price of $2.3 million. On July 31, 2009, we sold substantially all of the remaining assets of RHL related to its wholesale and direct-to-consumer business to PharmaCare US Inc. and PharmaCare Laboratories Pty Ltd. for a purchase price of $500,000. We had the potential to receive up to an additional $500,000 from the buyers as a conditional earn-out if the RHL business acquired by the buyers met or exceeded certain budgeted profitability criteria during the period August 1, 2009 through July 31, 2010. Effective as of February 12, 2010, based on the loss of one or more customers, the results of operation of the RHL business since the closing date of the sale, the anticipated results of operation of the RHL business through July 31, 2010, and the corresponding anticipated reduction in and/or elimination of the conditional earn-out amount, and in an effort to avoid the time and expense associated with the procedures required in connection with the earn-out, including, without limitation, the time and expense associated with the preparation of the required reports and a review of the books and records of PharmaCare US and PharmaCare Australia, we entered into an agreement with PharmaCare to eliminate the potential earn-out compensation. Following the sale of substantially all of the assets of RHL on July 31, 2009, we changed the name of RHL to Disposition Company, Inc. The financial information presented in this report has been reclassified to reflect the legacy RHL business as discontinued operations.
Our research and development expenses for the last two fiscal years ended June 30 were $1.3 million for 2010 and $1.2 million for 2009.
Read the The complete Report
Natural Alternatives International Inc. has a market cap of $55 million; its shares were traded at around $7.75 with a P/E ratio of 11 and P/S ratio of 0.7. NAII is in the portfolios of Jim Simons of Renaissance Technologies LLC.
Highlight of Business Operations:
The aggregate market value of NAIs common stock held by non-affiliates of NAI as of the last business day of NAIs most recently completed second fiscal quarter (December 31, 2009) was approximately $44,433,385 (based on the closing sale price of $7.75 reported by Nasdaq on December 31, 2009). For this purpose, all of NAIs officers and directors and their affiliates were assumed to be affiliates of NAI.On December 5, 2005, we acquired Real Health Laboratories, Inc. (RHL), which primarily marketed branded nutritional supplements. On August 4, 2008, we sold certain assets related to RHLs catalog and internet business conducted under the name As We Change® to Miles Kimball Company for a cash purchase price of $2.3 million. On July 31, 2009, we sold substantially all of the remaining assets of RHL related to its wholesale and direct-to-consumer business to PharmaCare US Inc. and PharmaCare Laboratories Pty Ltd. for a purchase price of $500,000. We had the potential to receive up to an additional $500,000 from the buyers as a conditional earn-out if the RHL business acquired by the buyers met or exceeded certain budgeted profitability criteria during the period August 1, 2009 through July 31, 2010. Effective as of February 12, 2010, based on the loss of one or more customers, the results of operation of the RHL business since the closing date of the sale, the anticipated results of operation of the RHL business through July 31, 2010, and the corresponding anticipated reduction in and/or elimination of the conditional earn-out amount, and in an effort to avoid the time and expense associated with the procedures required in connection with the earn-out, including, without limitation, the time and expense associated with the preparation of the required reports and a review of the books and records of PharmaCare US and PharmaCare Australia, we entered into an agreement with PharmaCare to eliminate the potential earn-out compensation. Following the sale of substantially all of the assets of RHL on July 31, 2009, we changed the name of RHL to Disposition Company, Inc. The financial information presented in this report has been reclassified to reflect the legacy RHL business as discontinued operations.
Our research and development expenses for the last two fiscal years ended June 30 were $1.3 million for 2010 and $1.2 million for 2009.
Read the The complete Report
